We then treated HEL and SET-2 cells and BMMNCs from MPN patients with Romidepsin, and observed that the mRNA levels of GADD45g were upregulated more than 4-fold in the cell lines (Fig. 10m), and approximately 3- to 4-fold in primary BMMNCs (Fig. 10n). Here, GADD45G is linked to myeloproliferative disorder.